Worldwide Drug Discovery R&D

Content

• 1. Current Status
  • 1.1 Rx Drug Discovery R&D Steps and Timelines
  • 1.2 Review of Rx R&D Progress
    • 1.2.1 Drug R&D Productivity Trends
    • 1.2.2 Annual Pharma Industry R&D Budgets
    • 1.2.3 Annual Regulatory Approval Trends
  • 1.3 Disease Demographics in the Developed World
    • 1.3.1 Pharma Companies Use Disease Demographics in R&D Planning
    • 1.3.2 Monitoring and Analyzing Population Health Data
    • 1.3.3 Major Disease Categories and Pharma Business Opportunities
• 2. Cancer, Gastrointestinal and Metablolic Disease Drug R&D Development Strategy by Company
  • 2.1 Cancer Drug R&D Development Activity and Strategy
  • 2.2 Cancer R&D Programs by Major Companies
  • Total 31 Companies
  • Common Research Item
  • R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
  • Researcher Comment
  • R&D Drug Pipeline: Clinical Trials by Therapy (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
  • 2.3 Gastrointestinal Disease Drug R&D Development Activity and Strategy
  • 2.4 Gastrointestinal Disease R&D Programs by Major Company
  • Total 13 Companies
  • Common Research Item
  • R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
  • Researcher Comment
  • R&D Drug Pipeline: Clinical Trials by Therapy (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
  • 2.5 Metabolic Disease Drug R&D Development Activity and Strategy
  • 2.6 Metabolic Disease R&D Programs by Major Company
  • Total 12 Companies
  • Common Research Item
  • R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
  • Researcher Comment
  • R&D Drug Pipeline: Clinical Trials by Therapy (Product Name, Generic Name, Indication, hase, Target Year, Market Size ($)
• 3. CNS, Infectious Disease, Respiratory and Urogenital Disease Drug R&D Development Strategy by Company
  • 3.1 CNS Drug R&D Development Activity and Strategy
  • 3.2 CNS Drug R&D by Major Company
  • Total 24 Companies
  • Common Research Item
  • R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
  • Researcher Comment
  • R&D Drug Pipeline: Clinical Trials by Therapy (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
  • 3.3 Infectious Disease Drug R&D Development Activity and Strategy
  • 3.4 Infectious Disease Drug R&D by Major Company
  • Total 22 Companies
  • Common Research Item
  • R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
  • Researcher Comment
  • R&D Drug Pipeline: Clinical Trials by Therapy (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
  • 3.5 Respiratory Drug R&D Development Activity and Strategy
  • 3.6 Respiratory Drug R&D by Major Company
  • Total 11Companies
  • Common Research Item
  • R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
  • Researcher Comment
  • R&D Drug Pipeline: Clinical Trials by Therapy (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
  • 3.7 Urogenital Drug R&D Development Activity and Strategy
  • 3.8 Urogenital Drug R&D by Major Company
  • Total 11 Companies
  • Common Research Item
  • R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
  • Researcher Comment
  • R&D Drug Pipeline: Clinical Trials by Therapy (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
• 4. Cardiovascular, Musculoskeletal and Other Disease Drug R&D Development Strategy by Company
  • 4.1 Cardiovascular Disease Drug R&D Development Activity and Strategy
  • 4.2 Cardiovascular Disease Drug R&D by Major Company
  • Total 21 Companies
  • Common Research Item
  • R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
  • Researcher Comment
  • R&D Drug Pipeline: Clinical Trials by Therapy (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
  • 4.3 Musculoskeletal Disease Drug R&D Development Activity and Strategy
  • 4.4 Musculoskeletal Disease Drug R&D by Major Company
  • Total 11 Companies
  • Common Research Item
  • R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
  • Researcher Comment
  • R&D Drug Pipeline: Clinical Trials by Therapy (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
  • 4.5 'Other Disease' Drug R&D Development Activity and Strategy
  • 4.6 'Other Disease' Drug R&D by Major Company
  • Total 14 Companies
  • Common Research Item
  • R&D Structure (R&D Budget, # of Researchers, Strategic Alliance)
  • Researcher Comment
  • R&D Drug Pipeline: Clinical Trials by Therapy (Product Name, Generic Name, Indication, Phase, Target Year, Market Size ($)
• 5. Analysis of Top Rx Drug R&D Vendors vs. Competitors
  • 5.1 Cancer Indications: Analysis of Drug R&D Competitors By Value Factor
  • 5.2 Cardiovascular Indications: Analysis of Drug R&D Competitors By Value Factor
  • 5.3 CNS Indications: Analysis of Drug R&D Competitors By Value Factor
  • 5.4 Gastrointestinal Indications: Analysis of Drug R&D Competitors By Value Factor
  • 5.5 Infectious Disease Indications: Analysis of Drug R&D Competitors By Value Factor
  • 5.6 Metabolic Indications: Analysis of Drug R&D Competitors By Value Factor
  • 5.7 Musculoskeletal Indications: Analysis of Drug R&D Competitors By Value Factor
  • 5.8 Respiratory Indications: Analysis of Drug R&D Competitors By Value Factor
  • 5.9 rogenital Indications: Analysis of Drug R&D Competitors By Value Factor
  • 5.10 'Other' Indications: Analysis of Drug R&D Competitors By Value Factor
  • 5.11 Summary of Analysis
    • 5.11.1 Main Findings
    • 5.11.2 Leading Five Therapy Areas
    • 5.11.3 Competition: Big Rx Companies vs. Small Rx Companies
• 6. Identifying Potential Blockbusters
  • 6.1 Top Therapy Areas
  • 6.2 Top Potential Blockbusters
• 7. Conclusions and Other Thoughts
  • 7.1 Drug R&D Progress and Trends
  • 7.2 Disease Demographics Can Shape Pharma Markets
  • 7.3 Drug R&D by Therapy Areas and Competition
  • 7.4 Finding Potential Blockbuster Drugs
  • 7.5 Other Thoughts
• 8. Appendix 1 - Links to Small Pharmaceutical Companies Mentioned in Data Tables
• 9. Appendix 2 - Links to Worldwide Human Drug Regulatory Organizations
• List of Tables
  • Table 1. Pharma R&D Productivity by Approved NMEs, 1994-2004E
  • Table 2. Pharma Industry R&D Spending vs. US NIH FY Budgets, 1994-2004E
  • Table 3. Median FDA Approval Timelines and Approved NMEs 1994-2004
  • Table 4. Summary of Patient Populations Sorted by Total Existing Patients
  • Table 5. Estimated Patient Populations by Disease in the Developed World
  • Table 6. Top 5 Health Risk Factors Leading to Death
  • Table 7. Cancer Drug Pipelines by Indication
  • Table 8. Gastrointestinal Disease Drug Pipelines by Indication
  • Table 9. Metabolic Disease Drug Pipelines by Indication
  • Table 10. CNS Drug Pipelines by Indication
  • Table 11. Infectious Disease Drug Pipelines by Indication
  • Table 12. Respiratory Drug Pipelines by Indication
  • Table 13. Urogenital Drug Pipelines by Indication
  • Table 14. Cardiovascular Drug Pipelines by Indication
  • Table 15. Musculoskeletal Drug Pipelines by Indication
  • Table 16. 'Other Disease' Drug Pipelines by Indication
  • Table 17. Top Cancer Indications Sorted By Value Factor
  • Table 18. Cancer Indications, Top Companies & Rx's in R&D By Value Factor
  • Table 19. Top Cardiovascular Indications By Value Factor
  • Table 20. Cardiovascular Indications, Top Companies & Rx's in R&D By Value Factor
  • Table 21. Top CNS Indications By Value Factor
  • Table 22. CNS Indications, Top Companies & Rx's in R&D By Value Factor
  • Table 23. Top Gastrointestinal Indications By Value Factor
  • Table 24. Gastrointestinal Indications, Top Companies & Rx's in R&D By Value Factor
  • Table 25. Top Infection Indications By Value Factor
  • Table 26. Infectious Disease Indications, Top Companies & Rx's in R&D By Value Factor
  • Table 27. Top Metabolic Indications By Value Factor
  • Table 28. Metabolic Disease Indications, Top Companies & Rx's in R&D By Value Factor
  • Table 29. Top Musculoskeletal Indications By Value Factor
  • Table 30. Musculoskeletal Indications, Top Companies & Rx's in R&D By Value Factor
  • Table 31. Top Respiratory Indications By Value Factor
  • Table 32. Respiratory Indications, Top Companies & Rx's in R&D By Value Factor
  • Table 33. Top Urogenital Indications By Value Factor
  • Table 34. Urogenital Indications, Top Companies & Rx's in R&D By Value Factor
  • Table 35. Top 'Other' Indications By Value Factor
  • Table 36. 'Other' Indications, Top Companies & Rx's in R&D By Value Factor
  • Table 37. Summary of Analysis by Major Therapy Area and Value Factor
  • Table 38. Major Therapy Areas by Number of Blockbuster Drugs
  • Table 39. Estimated Revenues of Potential Blockbusters by Year of Release
  • Table 40. Cancer Drugs, Peak Market Potential and Est. Launch Year
  • Table 41. Cardiovascular Drugs, Peak Market Potential and Est. Launch Year
  • Table 42. CNS Drugs, Peak Market Potential and Est. Launch Year
  • Table 43. Gastrointestinal Drugs, Peak Market Potential and Est. Launch Year
  • Table 44. Infectious Disease Drugs, Peak Market Potential and Est. Launch Year
  • Table 45. Metabolic Drugs, Peak Market Potential and Est. Launch Year
  • Table 46. Musculoskeletal Drugs, Peak Market Potential and Est. Launch Year
  • Table 47. Respiratory Drugs, Peak Market Potential and Est. Launch Year
  • Table 48. Urogenital Drugs, Peak Market Potential and Est. Launch Year
  • Table 49. 'Other' Drugs, Peak Market Potential and Est. Launch Year
• List of Figures
  • Figure 1. Drug R&D and Approval Process for New Rx Products
  • Figure 2. Pharma R&D Productivity by Approved NMEs, 1994-2004E
  • Figure 3. Pharma Industry R&D Spending vs. US NIH FY Budgets, 1994-2004E
  • Figure 4. Median FDA Approval Timelines and Approved NMEs 1994-2004